Your browser doesn't support javascript.
loading
The impact of vaccination on COVID-19 outbreaks in the United States
Seyed M. Moghadas; Thomas N. Vilches; Kevin Zhang; Chad R. Wells; Affan Shoukat; Burton H. Singer; Lauren Ancel Meyers; Kathleen M. Neuzil; Joanne M. Langley; Meagan C. Fitzpatrick; Alison P. Galvani.
Affiliation
  • Seyed M. Moghadas; York University
  • Thomas N. Vilches; University of Campinas
  • Kevin Zhang; University of Toronto
  • Chad R. Wells; Yale University
  • Affan Shoukat; Yale University
  • Burton H. Singer; University of Florida
  • Lauren Ancel Meyers; The University of Texas at Austin
  • Kathleen M. Neuzil; University of Maryland
  • Joanne M. Langley; Dalhousie University
  • Meagan C. Fitzpatrick; University of Maryland
  • Alison P. Galvani; Yale University
Preprint in English | medRxiv | ID: ppmedrxiv-20240051
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
BackgroundGlobal vaccine development efforts have been accelerated in response to the devastating COVID-19 pandemic. We evaluated the impact of a 2-dose COVID-19 vaccination campaign on reducing incidence, hospitalizations, and deaths in the United States (US). MethodsWe developed an agent-based model of SARS-CoV-2 transmission and parameterized it with US demographics and age-specific COVID-19 outcomes. Healthcare workers and high-risk individuals were prioritized for vaccination, while children under 18 years of age were not vaccinated. We considered a vaccine efficacy of 95% against disease following 2 doses administered 21 days apart achieving 40% vaccine coverage of the overall population within 284 days. We varied vaccine efficacy against infection, and specified 10% pre-existing population immunity for the base-case scenario. The model was calibrated to an effective reproduction number of 1.2, accounting for current non-pharmaceutical interventions in the US. ResultsVaccination reduced the overall attack rate to 4.6% (95% CrI 4.3% - 5.0%) from 9.0% (95% CrI 8.4% - 9.4%) without vaccination, over 300 days. The highest relative reduction (54-62%) was observed among individuals aged 65 and older. Vaccination markedly reduced adverse outcomes, with non-ICU hospitalizations, ICU hospitalizations, and deaths decreasing by 63.5% (95% CrI 60.3% - 66.7%), 65.6% (95% CrI 62.2% - 68.6%), and 69.3% (95% CrI 65.5% - 73.1%), respectively, across the same period. ConclusionsOur results indicate that vaccination can have a substantial impact on mitigating COVID-19 outbreaks, even with limited protection against infection. However, continued compliance with non-pharmaceutical interventions is essential to achieve this impact. Key pointsVaccination with a 95% efficacy against disease could substantially mitigate future attack rates, hospitalizations, and deaths, even if only adults are vaccinated. Non-pharmaceutical interventions remain an important part of outbreak response as vaccines are distributed over time.
License
cc_by_nc_nd
Full text: Available Collection: Preprints Database: medRxiv Type of study: Experimental_studies / Observational study / Prognostic study Language: English Year: 2020 Document type: Preprint
Full text: Available Collection: Preprints Database: medRxiv Type of study: Experimental_studies / Observational study / Prognostic study Language: English Year: 2020 Document type: Preprint
...